[go: up one dir, main page]

CO5050328A1 - SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS - Google Patents

SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS

Info

Publication number
CO5050328A1
CO5050328A1 CO98017937A CO98017937A CO5050328A1 CO 5050328 A1 CO5050328 A1 CO 5050328A1 CO 98017937 A CO98017937 A CO 98017937A CO 98017937 A CO98017937 A CO 98017937A CO 5050328 A1 CO5050328 A1 CO 5050328A1
Authority
CO
Colombia
Prior art keywords
solvent system
pharmaceutical compounds
best penetration
penetration
composition
Prior art date
Application number
CO98017937A
Other languages
Spanish (es)
Inventor
S Rao Chakradhara
Liu Jue-Chen
Jonas C T Wang
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of CO5050328A1 publication Critical patent/CO5050328A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE UNA COMPOSICION QUE CONSISTE DE UN COM PUESTO O DROGA FARMACEUTICAMENTE TOPICAMENTE ACTI- VO Y UN SISTEMA SOLVENTE BUFFER CAPAZ DE MEJORAR LA PENETRACION DE DICHA DROGA. EL SISTEMA SOLVEN- TE BUFFER PERMITE A UNA CANTIDAD REDUCIDA DEL COM- PUESTO FARMACEUTICO DE LA COMPOSICION NO ALTERAR SIGNIFICATIVAMENTE LA EFICACIA DE DICHO COMPUESTO.A COMPOSITION IS DESCRIBED WHICH CONSISTS OF A PHARMACEUTICALLY TOPICALLY ACTIVENT COMMITTEE OR DRUG AND A SOLELY BUFFER SYSTEM ABLE TO IMPROVE THE PENETRATION OF THE DRUG. THE BUFFER SOLVING SYSTEM ALLOWS A REDUCED AMOUNT OF THE PHARMACEUTICAL COMPOSITION COMPOSITION NOT TO SIGNIFICANTLY ALTER THE EFFECTIVENESS OF THIS COMPOSITE.

CO98017937A 1997-03-31 1998-03-31 SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS CO5050328A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82909197A 1997-03-31 1997-03-31

Publications (1)

Publication Number Publication Date
CO5050328A1 true CO5050328A1 (en) 2001-06-27

Family

ID=25253504

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98017937A CO5050328A1 (en) 1997-03-31 1998-03-31 SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS

Country Status (14)

Country Link
EP (1) EP0971746A1 (en)
JP (1) JP2001518879A (en)
KR (1) KR19980081207A (en)
CN (1) CN1252003A (en)
AR (1) AR012217A1 (en)
AU (1) AU6677698A (en)
BR (1) BR9811458A (en)
CA (1) CA2285368A1 (en)
CO (1) CO5050328A1 (en)
HU (1) HUP0001739A3 (en)
IL (1) IL132096A0 (en)
PL (1) PL335934A1 (en)
WO (1) WO1998043673A1 (en)
ZA (1) ZA982662B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232855C (en) * 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
WO2000072818A1 (en) * 1999-05-27 2000-12-07 The Procter & Gamble Company Topical compositions providing improved treatment of skin or scalp fungal infections
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP4784051B2 (en) * 2003-07-03 2011-09-28 大正製薬株式会社 Antifungal composition for external use that prevents adsorption to the container
JP5435836B2 (en) * 2003-07-03 2014-03-05 大正製薬株式会社 Antifungal composition for external use
DE102005059742A1 (en) 2005-12-13 2007-06-14 Beiersdorf Ag Transparent sunscreen
US20080032994A1 (en) 2006-08-03 2008-02-07 Marcel Borgers Modified azole compounds as antifungal and antibacterial agents
DE602008002692D1 (en) * 2007-07-25 2010-11-04 Ixodes Gmbh TOPICAL ANTIBIOTIC COMPOSITION FOR THE PREVENTION OF LYME BORRELIOSIS
PL2191825T3 (en) * 2007-08-27 2016-11-30 Agent for fungal dermatitis
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US9839611B2 (en) * 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
MX363386B (en) 2013-10-03 2019-03-20 Dow Pharmaceutical Sciences Stabilized efinaconazole compositions.
CN105848719A (en) 2013-11-22 2016-08-10 道尔医药科学公司 Anti-infective methods, compositions, and devices
CN115745757B (en) * 2022-11-07 2024-04-26 中国人民解放军军事科学院军事医学研究院 Synthesis of a liquid polyglycol pillar aromatic derivative and its application in transdermal sustained release of pharmacodynamic molecules
WO2024238892A2 (en) * 2023-05-18 2024-11-21 Coast Southwest, Inc. Acidic skin and/or hair compositions and methods thereof
WO2025080638A1 (en) * 2023-10-09 2025-04-17 Dr. Anti Fungus, LLC Active pharmaceutical ingredient compositions and preparation and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331137C (en) * 1988-02-29 1994-08-02 Pfizer, Inc. Transdermal flux enhancing compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
CN1106259A (en) * 1994-02-05 1995-08-09 日东制药株式会社 Antiphlogistic and analgesic gel agent for external use containing propanoic acid non steroid pharmaceutical as effective composition

Also Published As

Publication number Publication date
PL335934A1 (en) 2000-05-22
BR9811458A (en) 2000-09-19
EP0971746A1 (en) 2000-01-19
JP2001518879A (en) 2001-10-16
CA2285368A1 (en) 1998-10-08
IL132096A0 (en) 2001-03-19
AU6677698A (en) 1998-10-22
ZA982662B (en) 1999-09-30
AR012217A1 (en) 2000-09-27
KR19980081207A (en) 1998-11-25
WO1998043673A1 (en) 1998-10-08
CN1252003A (en) 2000-05-03
HUP0001739A3 (en) 2001-04-28
HUP0001739A2 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
CO5050328A1 (en) SOLVENT SYSTEM FOR THE BEST PENETRATION OF PHARMACEUTICAL COMPOUNDS
MX9302448A (en) CYCLICAL IMINIC DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND MEDICINES CONTAINED IN THESE COMPOUNDS.
GT199700009A (en) COMBINED THERAPY FOR OSTEOPOROSIS.
GT199900070A (en) DERIVATIVES OF ISOTIAZOLE, USEFUL AS ANTI-CANCER AGENTS.
MX9505182A (en) Therapeutical composition for topical application, containing a p substance antagonist.
MX9202407A (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ALYLAMINE COMPOUND AS THE ACTIVE AGENT AND PROCESS FOR ITS PREPARATION.
BR9714517A (en) Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising them and processes to inhibit beta-amyloid peptide release and / or its synthesis by using such compounds
GT199700089A (en) DERIVATIVES 6.6 OR 6.7-SUBSTITUTED BICYCLES CONTAINING PIRIDO OR PIRIMIDO.
UY27943A1 (en) COMPOSITIONS AND METHODS TO TREAT CRNCER USING ANTIBODY IMMUNOCATE PLAYS FOR CD44 CYTOTNXICS AND CHEMOTHERAPCUTIC AGENTS
GT199700079A (en) TRICYCLES DERIVATIVES REPLACED WITH PHENYLAMINE
KR960701661A (en) HIV protease inhibitors in pharmaceutical combinations for the treament of AIDS
BR0015605A (en) Composition and use
AR012671A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PROPHYLAXIS OF THE CONSTIPATION, THE USES OF SUCH COMPOSITIONS AND THE PROCESSES TO PREPARE THEM
AR058193A1 (en) PHARMACEUTICAL COMPOSITIONS
AR021912A1 (en) USE OF APOMORPHINE FOR THE TREATMENT OF ORGANIC ERECTILE DYSFUNCTION IN VARONES
AR025052A1 (en) DERIVATIVES OF 2-DIALQUILAMINOALQUILBIFENILO SUBSTITUTED, PROCEDURE FOR PREPARATION, MEDICATIONS CONTAINING THESE COMPOUNDS AND THE USE OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES.
AR042051A1 (en) COMBINED TREATMENT AGAINST CANCER WITH AN ANTI-CANCERIGENE COMPOUND ACTIVATED BY GLUTATIONA S- TRANSFERASA (GST) AND OTHER TREATMENT AGAINST CANCER
MX9306220A (en) PTP 1D: A NOVYOSE THYROSINE PHOSPHATASE PROTEIN.
AR003119A1 (en) PHARMACEUTICAL COMPOSITION FOR TREATING VIROSIC INFECTIONS OR INHIBITING THE GROWTH OF TUMORS OR CANCERES WHICH INCLUDE A MIXTURE OF A N-CHLOROPHENYL CARBAMATE OR A N-CHLOROPHENITIC CARBAMATE AND A N- PHOSPHONOGLYCAN FOR DICHAUTIC DURATION INHIBIT THE GROWTH OF TUMORS OR CANCERS
AR003176A1 (en) A PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF CANCER
AR006401A1 (en) PIRROLOPYROLONE COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND IN THERAPY, PROCESSES FOR ITS PREPARATION AND INTERMEDIARY COMPOUNDS FOR SUCH PROCESSES.
BR0208017A (en) Combination comprising combretastatin and anticancer agents
BR0012442A (en) Drug with protective action against toxic oxidizing substances and particularly against cardiotoxic substances
PA8515601A1 (en) THE USE OF COMPOSITIONS BASED ON ANTIBIOTICS OF AZALIDOS TO TREAT OR PREVENT A BACTERIAL OR PROTOZOARY INFECTION IN MAMMALS
ES2156220T3 (en) TRANSDERMIC PREPARATION CONTAINING A LORATIDINE METABOLITE WITH ANTIHISTAMINAL ACTION.